urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical Universityurmj-61Research ArticleОНКОМОРФОЛОГИЯПрогностическое значение оценки морфологического регресса метастазов наследственных опухолей яичника в большой сальник после неоадъювантной химиотерапииThe prognostic significance of the omental chemotherapy response score in hereditary ovarian tumors after neoadjuvant chemotherapyИванцовАлександр ОлеговичIvantsovA. O.shurikiv@mail.ruКлещёвМ. А.KleshchovM. A.noemail@neicon.ruГородноваТ. В.GorodnovaT. V.noemail@neicon.ruКотивХ. Б.KotivK. B.noemail@neicon.ruИмянитовЕ. Н.ImyanitovE. N.noemail@neicon.ruСоколенкоА. П.SokolenkoA. P.noemail@neicon.ruФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава РоссииRussian Federation201814042021023942Copyright © Иванцов А.О., Клещёв М.А., Городнова Т.В., Котив Х.Б., Имянитов Е.Н., Соколенко А.П., 20212021Иванцов А.О., Клещёв М.А., Городнова Т.В., Котив Х.Б., Имянитов Е.Н., Соколенко А.П.Ivantsov A.O., Kleshchov M.A., Gorodnova T.V., Kotiv K.B., Imyanitov E.N., Sokolenko A.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/61

Целью данного исследования стало сравнение выраженности патоморфологического регресса метастазов в большой сальник BRCA1-ассоциированных и спорадических опухолей яичника в ответ на платиносодержащую неоадъювантную химиотерапию (НАХТ). В исследование включены 40 пациенток (16 больных с мутацией BRCA1 и 24 «спорадических» случаев) в соответствии с следующими критериями: серозный гистотип опухоли высокой степени злокачественности, платиносодержащая НАХТ, оптимальная циторедуктивная операция (ОЦО), известная длительность бесплатинового интервала (БПИ). При оценке гистопатологического регресса метастазов в большой сальник в группе BRCA1-ассоциированного рака яичника РЯ частота выраженных регрессов [3 балла] составила 4/16 (25%), в группе спорадических опухолей - 1/24 (4%) (p = 0,14, точный критерий Фишера). Продолжительность БПИ достоверно зависела от степени регресса (при минимальном регрессе медиана составила 3,62 мес., при умеренном - 8,17 мес., при выраженном - 21,28 мес.; p = 0,026, тест Краскела-Уоллиса). В группе носителей мутаций BRCA1 наблюдалось различие в продолжительности БПИ между случаями с умеренным и выраженным регрессом и случаями с минимальным регрессом (медианы 18,6 мес. vs. 2,9 мес., соответственно; p = 0,04, критерий Манна-Уитни). Степень выраженности патоморфологического регресса метастазов в большой сальник BRCA1-ассоциированных и спорадических опухолей яичника в ответ на НАХТ после ОЦО коррелирует с продолжительностью БПИ.

The study was aimed to evaluate histopathological tumor response of omental metastases in BRCA1-associated and sporadic ovarian tumors after platinum-based neoadjuvant chemotherapy (NACT). We selected patients with histologically confirmed ovarian high-grade serous carcinoma who were treated with NACT followed by optimal debulking. Forty patients (14 BRCA1-associated cancers and 26 sporadic cases) meeting the criteria mentioned above were enrolled in the pathological examination. Clinical data (platinum-free interval, PFI) were collected through database review. Good regress [score 3] was observed in 4 out of 16 (25%) BRCA1-associated carcinomas and in one of 24 (4%) sporadic cancers (p = 0.14, Fisher's exact test). PFI was associated with the degree of response (minimal regress - median PFI 3.62 months, moderate regress - median 8.17 months, good regress - 21.28 months, p = 0.026, Kruskal-Wallis test). The omental response score predicted platinum-free interval in BRCA1-associated tumors (score 2+3 vs. 1; median PFI, 18.6 vs. 2.9 months; p = 0.04, Mann-Whitney U test). Histopathological tumor response of omental metastasis in BRCA1-associated and sporadic ovarian tumors after platinum-based neoadjuvant chemotherapy predicts PFI.

мутация BRCA1рак яичниковнеоадъювантная химиотерапияBRCA1 mutationovarian cancerneoadjuvant chemotherapyReferencesTropé C.G., Elstrand M.B., Sandstad B., et al. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?, Eur. J. Cancer 48 (14) (2012) 2146-2154.Tropé C.G., Elstrand M.B., Sandstad B., et al. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?, Eur. J. Cancer 48 (14) (2012) 2146-2154.Böhm S., Faruqi A., Said I., et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol. 2015 Aug 1;33(22):2457-63.Böhm S., Faruqi A., Said I., et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol. 2015 Aug 1;33(22):2457-63.Lee J.Y., Chung Y.S., Na K., et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. 2017 Nov;28(6):e73.Lee J.Y., Chung Y.S., Na K., et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. 2017 Nov;28(6):e73.Tan D.S., Rothermundt C., Thomas K. et al. «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome ofpatients with epithelial ovarian cancer associated with BRCA1 and BRCA2 // J. Clin. Oncol. 2008. Vol. 26 (34). P. 5530-5536.Tan D.S., Rothermundt C., Thomas K. et al. «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome ofpatients with epithelial ovarian cancer associated with BRCA1 and BRCA2 // J. Clin. Oncol. 2008. Vol. 26 (34). P. 5530-5536.Petrillo M., Zannoni G.F., Tortorella L., et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. AM J Obstet Gynecol. 2014; 211: 632. e1-8.Petrillo M., Zannoni G.F., Tortorella L., et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. AM J Obstet Gynecol. 2014; 211: 632. e1-8.Sokolenko A.P., Savonevich E.L., Ivantsov A.O., et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017 Jul 1;397:127-132.Sokolenko A.P., Savonevich E.L., Ivantsov A.O., et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017 Jul 1;397:127-132.Said I., Böhm S., Beasley J., et al. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. Int J Gynecol Pathol. 2017; 36(2):172-179.Said I., Böhm S., Beasley J., et al. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. Int J Gynecol Pathol. 2017; 36(2):172-179.Gorodnova T.V., Sokolenko A.P., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett. 2015; 369(2):363-7.Gorodnova T.V., Sokolenko A.P., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett. 2015; 369(2):363-7.Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32.Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32.Sassen S., Schmalfeldt B., Avril N., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38:926-934.Sassen S., Schmalfeldt B., Avril N., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38:926-934.

The authors declare that there are no conflicts of interest present.